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Introduction
B-cell chronic lymphocytic leukaemia (B-CLL) is a
disorder characterized by clonal proliferation and
accumulation of mature lymphoid cells of low prolif-
erative potential due to disturbance of preset genetical-
ly regulated death of cells called apoptosis [1]. Apop-
tosis may be induced through the extrinsic or intrinsic
pathway. Bcl-2 family proteins trigger the intrinsic, i.a.
mitochondrial pathway of apoptosis [2]. Some of these
proteins are responsible for precipitating changes typ-
ical for apoptosis in mitochondria, which are followed
with activation of proteolytic cleavage and caspases,
such as Bcl-x and Bax. The latter inhibit apoptotic cas-
cade of Bcl-xL, Bcl-2 or Mcl-1 [3,4]. Bcl-2 is a mem-
brane-bound protein that, due to the ability to inacti-
vate free radicals and influence on calcium ions distri-
bution, protects cells from death by apoptosis. Bax
protein has a proapoptotic function. It is responsible
for causing changes typical for apoptosis in mitochon-
dria, e.g. loss of electrochemical gradient, secretion of
cytochrome c and calcium ions from mitochondrial
matrix, which lead to activation of proteolytic process-
es and caspases. Bax and Bcl-2 protein constitute con-
nections in the form of heterodimers or larger con-
glomerates. Bcl-xL proteins extend life span of a cell,
whereas Bcl-xs has an apoptotic function. Bcl-2 fami-
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Abstract: B-cell chronic lymphocytic leukaemia (B-CLL) is characterized by clonal growth and accumulation of mature lym-
phoid cells due to disturbance in genetically regulated form of cell death called apoptosis. The intrinsic mechanism of apopto-
sis is controlled by Bcl-2 family proteins. Purine nucleoside analogues induce the apoptosis in cells in a state of quiescence.
The aim of the study was to assess expression of selected Bcl-2 family proteins in neoplastic infiltration in bone marrow in
patients with B-CLL treated with nucleoside analogues. The study comprised examination of bone marrow obtained routinely
by trephine biopsy from 18 patients with B-CLL diagnosed before administration of purine nucleoside analogues treatment and
after its completion. Expression of Bcl-2, Bcl-x and Bax proteins was examined. Lymphoid cells in bone marrow were present
in all patients before administration of treatment. After treatment in two patients bone marrow was infiltrated in diffuse pattern,
whereas other patients presented nodular pattern of infiltration. The difference between stage of infiltration before and after
treatment was statistically significant (p<0.002). High percentage of infiltration cells with positive anti Bcl-2 reaction from
42.0% in one patient to 85.33±3.06% in four patients before treatment was observed. After treatment percentage of infiltration
cells with positive anti Bcl-2 antibody reaction was from 33.0±18.38% in two patients to 99.0% in one patient. Positive corre-
lation between stage of infiltration and expression of Bcl-2 protein was confirmed before and after treatment. Such correlations
were not observed in case of Bax and Bcl-x. Strong staining of immunohistochemical reaction of cells in lymphoid infiltration
with Bcl-2 antibody was confirmed. There was a difference between Bcl-/Bax ratio before and after treatment. Immunohisto-
chemical assessment of expression of Bcl-2 family proteins in cells of lymphoid infiltration in bone marrow of patients with
CLL is an important method in detection of minimal residual disease (MRD) after treatment.
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ly proteins regulate life span of cells and therefore play
an important role in etiology and survivability of neo-
plastic cells and acquired resistance to antineoplastic
treatment [4,5]. Excessive expression of the Bcl-2 pro-
tein is associated with a block in apoptosis. Mutations of
p53 are associated with drug resistance [6]. New purine
nucleoside analogues, such as deoxycoformycin (pento-
statin, dCF), 2-chlordeoxyadenosine (2-CdA, cladrib-
ine) and fludarabine (FAMP), influence cells in a state
of quiescence by inducing apoptosis [7-9]. Histological
examination of bone marrow obtained by trephine biop-
sy (TB) is not obligatory in diagnosis of B-CLL. How-
ever, it is a useful diagnostic procedure in monitoring
the course of the disease, its prognosis and assessment
of MRD (minimal residual disease), i.a. nodular partial
remission (nPR) in bone marrow [10-12]. In B-CLL
leukaemic cells may infiltrate bone marrow in a diffuse,
nodular, interstitial and mixed (nodular/interstitial) pat-
tern. It was observed that the patients with diffuse pat-
tern of infiltration in bone marrow tend to develop more
advanced form of the disease and therefore relatively
poor prognosis [13]. 
The aim of the study was to assess expression of
Bcl-2, Bax and Bcl-x in neoplastic infiltration in bone
marrow in patients with B-CLL treated with nucleo-
side analogues.
Material and methods
Bone marrow samples. The bone marrow was obtained by routine
TB of posterior superior iliac spine in accordance with clinical
indications from 18 newly diagnosed, untreated patients (8 women
and 10 men, aged 35-72), with B-CLL at the II, III or IV clinical
stage of the disease according to Rai staging system. The diagno-
sis of B-CLL was strictly confirmed by relevant clinical and cyto-
logical findings. TB was performed in every patient as initial
examination prior to chemotherapy and after six courses of treat-
ment. Bone marrow tissue material was fixed in so-called "Oxford
solution" (100 ml of 40% formaldehyde solution, 900 ml distilled
water, 8.7 g Natrium Chloride, 20 ml glacial acetic acid). After fix-
ing (48-72 hours), the cylinder-shaped bone marrow specimens 2
cm long and 1mm in diameter were put into paraffin bars. The bars
were cut in sections of 5 µm thickness and afterwards underwent
routine histological and immunohistochemical procedure. The
stage and the pattern of neoplastic infiltration were assessed (dif-
fuse, nodular, interstitial and mixed). 
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Table 1. Expression and intensity of immunohistochemical reaction in B-CLL patients before and after treatment
Immunohistochemistry. The origin of neoplastic cells forming
infiltration was confirmed by coupling with anti CD20 and anti
CD3 monoclonal antibody (DAKO Cytomation). Immunohisto-
chemical examinations were conducted with the help of specific
monoclonal Bcl-2, Bax antibodies and polyclonal Bcl-x antibodies
by DAKO Cytomation. Primary antibodies were used by dilution
according to the manufacturer's instructions. All sections required
microwave heating for receptor retrieval. A detecting kit for Bcl-2
was LSAB+KIT (DAKO Cytomation), and CSA System (DAKO
Cytomation) for Bax and Bcl-x. DAB (3, 3'- diaminobenzidine)
was used as a chromogen. If the reaction was positive brown-
coloured antigen-antibody complexes appeared in the position of a
protein receptor. Intensity of the positive reaction was defined
according to a three grade scale (from + to +++): (+) weak stain-
ing, (++) moderate staining, (+++) strong staining. Presence of
expression of proteins was defined as percentage value of neoplas-
tic cells with positive reaction to anti-Bcl-2, anti-Bax and anti-Bcl-
x in regard to total number of cells constituting neoplastic infiltra-
tion. Percentage value of neoplastic cells with positive reaction
was analysed with regard to morphometric analyser set Soft Imag-
ing System (OLYMPUS). The Bcl-2/Bax ratio before and after
treatment  was accounted. For negative control the sections under-
went the above procedure without primary antibodies. Positive
control for Bcl-2, Bax and Bcl-x antibodies was performed using
lymph node slices. Control group of the Bcl-2, Bax and Bcl-x
physiologic staining constituted five trephine biopsy specimens
obtained from patients without proliferative disease. 
Ethical issues. The study was approved by local Bioethical Com-
mittee of the Medical University of Bialystok no R-I-
003/204/2005.
Statistical analysis. Obtained results were analysed with the help
of the Wilcoxon matched pairs test and Spearman rank-order cor-
relation using the computer program StatisticaTM PL. 
Results
Infiltration of bone marrow by lymphoid cells was
observed in all patients before treatment. In fifteen
patients bone marrow was infiltrated in a diffuse pat-
tern and in three patients in a nodular pattern. After the
treatment the diffuse infiltration persisted only in two
patients. In the cases of a nodular pattern before treat-
ment, the stage of infiltration by lymphoid cells after
treatment was lower. Statistically significant differ-
ences were observed between infiltration stage before
treatment and after its completion (p<0.002). Very
high percentage value of cells with positive Bcl-2 reac-
tion was observed from 42.0% in one patient to
85.33±3.06% in four patients. After the treatment high
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Fig. 1. Correlation between the Bcl-2 expression and the stage of
lymphoid infiltration before and after treatment in B-CLL patients.
Fig. 2. Bcl-2/Bax ratio before and after treatment in each B-CLL
patient.
Fig. 3. The mean difference between Bcl-2/Bax ratio in lymphoid
infiltration before and after treatment in B-CLL patients.
expression of Bcl-2 was still present in other infiltra-
tion cells from 33.0±18.38% in two patients to 99.0%
in one patient. The results are presented in Table 1.
Correlation between Bcl-2 expression and the stage of
lymphoid infiltration before and after treatment was
shown (Fig. 1). Bax expression in infiltration cells was
accounted for 39.0±13.9% in five patients to 82.0% in
one patient. After the treatment percentage value of the
cells with positive anti-Bax reaction constituted from
10.0% in one patient to 62.8±12.68% in seven patients
(Table 1). Bcl-x expression in infiltration cells before
treatment was accounted for 36.0% in one patient to
62.0% in one patient. After the treatment percentage
value of the infiltration cells with positive anti-Bcl-x
reaction was accounted for 12.0% in one patient to
38.0% in two patients (Table 1). 
No correlation between Bcl-x and Bax, and the
stage of infiltration was found. The high Bcl-2/Bax
ratio before treatment was observed (Fig. 2). There
was a difference between Bcl-2/Bax ratio before and
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Fig. 4. Bone marrow trephine biopsy
section, B-CLL, diffuse infiltration.
Lymphoid cells with positive strong
staining for Bcl-2 antibody before
treatment (magnification ×240).
Fig. 5. Bone marrow trephine biopsy
section, B-CLL, nodular infiltration.
Lymphoid cells with positive strong
staining for Bcl-2 antibody after treat-
ment (magnification ×240).
after treatment (Fig. 3). In twelve patients strong stain-
ing (+++) of immunohistochemical reaction of infiltra-
tion cells with Bcl-2 was observed before treatment
(Fig. 4). Strong staining (+++) of immunohistochemi-
cal reaction of infiltration cells with anti-Bax appeared
in eleven patients. After treatment infiltration cells pre-
sented strong staining (+++) of immunohistochemical
reaction with anti Bcl-2 in ten patients, whereas with
Bax in thirteen patients (Fig. 5). In thirteen patients
strong staining (+++) of immunohistochemical reac-
tion of infiltration cells with anti Bcl-x before and after
the treatment was observed. In other cases the intensi-
ty of the positive reaction was moderate. In single
cases the intensity of the positive reaction was weak.
Differences between the intensity stage of immunohis-
tochemical reaction of infiltration cells with Bcl-2,
Bax and Bcl-x before and after the treatment that
appeared were not statistically significant. 
Discussion
Bcl-2 family proteins, by regulating life span of the
cells, play important role in etiology and progression
of neoplasms. Bcl-2 protein plays a key role in the
control of apoptosis [2]. In our study there was high
percentage of cells of neoplastic infiltration with posi-
tive anti-Bcl-2 reaction before treatment. Correlation
between the percentage of lymphoid cells and expres-
sion of Bcl-2 protein was shown. This supports obser-
vations, that excessive expression of this protein is one
of the most important factors in the development of
many neoplasms, including CLL. It is also significant
in the case of survival of neoplastic cells [6]. Exces-
sive expression of anti-apoptotic Bcl-2 family proteins
influences acquired resistance to antineoplastic treat-
ment [14,16]. In most cases of our study it turned out
that despite the administered treatment and change of
the infiltration pattern from diffuse into nodular, the
expression of Bcl-2 protein was still observed. This
suggests that lymphoid cells with disturbed mecha-
nism of apoptosis and excessive Bcl-2 expression were
still present. The nPR is often observed in patients with
CLL, which often suggests difficulties in achieving
total remission of the disease regardless of adminis-
tered treatment [11]. Nevertheless, purine nucleoside
analogues treatment seems to bear significance. In
most cases of our study considerable reduction of the
mass of neoplastic cells was observed. These medi-
cines can induce apoptosis in neoplastic cells [7]. Bcl-
2 is considered as a general apoptosis inhibitor so it is
very important to study new drugs like antisense
oligonucleotides, which with the help of other drugs
would overcome neoplastic cells resistance leading to
apoptosis [14-16]. 
In the literature it has been suggested that in acute
myeloid leukaemia, where overexpression of Bcl-2
occurs, the Bcl-2/Bax ratio is more significant than
absolute values of these proteins. The higher the ratio
is, the worse prognosis of achieving total remission of
the disease and event-free survival against recurrence
of the disease are [14]. In case of increased values of
Bcl-2/Bax ratio the raised cells' resistance to conven-
tional treatment is observed [17]. Our studies revealed
correlation between Bcl-2 and Bax proteins before
treatment. The Bcl-2/Bax ratio before treatment in the
most of cases was high which can prove worse prog-
nosis and lesser ability to obtain total remission in
those patients. Bcl-2 and Bax correlation was not con-
firmed after treatment. 
It has been suggested that neoplastic cells seem to
have disturbed mechanism of apoptosis due to Bcl-xL
protein [2,3]. In our studies polyclonal antibody Bcl-x
was used. Correlation between Bcl-x and the stage of
infiltration by lymphoid cells was not shown before
and after treatment. Strong staining of immunohisto-
chemical reaction defined as +++ was observed, which
indirectly suggests involvement of this protein in dis-
turbance of apoptosis. 
Bcl-2 protein which is present in neoplastic cells
is a sensitive marker of MRD in bone marrow [18]. In
our studies intensity of immunohistochemical reac-
tion was strong (+++) or moderate (++), which sup-
ports the possibility of performing tests on expression
of Bcl-2 family proteins in trephine biopsy specimens
of bone marrow. Bone marrow examination through
TB with the help of immunohistochemical methods
and image analysis supports its usefulness in progno-
sis of the course of the disease, assessment of effica-
cy of the administered treatment and MRD detection
[11,12,18].
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